EP1061919A4 - Neue opiate, verfahren zur ihrer herstellung und verwendung davon - Google Patents

Neue opiate, verfahren zur ihrer herstellung und verwendung davon

Info

Publication number
EP1061919A4
EP1061919A4 EP99912345A EP99912345A EP1061919A4 EP 1061919 A4 EP1061919 A4 EP 1061919A4 EP 99912345 A EP99912345 A EP 99912345A EP 99912345 A EP99912345 A EP 99912345A EP 1061919 A4 EP1061919 A4 EP 1061919A4
Authority
EP
European Patent Office
Prior art keywords
methods
making
opiate compounds
compounds
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99912345A
Other languages
English (en)
French (fr)
Other versions
EP1061919A1 (de
Inventor
Frank Ivy Carrol
S Wayne Mascarella
James B Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Triangle Institute
Original Assignee
Research Triangle Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Triangle Institute filed Critical Research Triangle Institute
Priority to EP04100891A priority Critical patent/EP1512683B1/de
Publication of EP1061919A1 publication Critical patent/EP1061919A1/de
Publication of EP1061919A4 publication Critical patent/EP1061919A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP99912345A 1998-03-10 1999-03-09 Neue opiate, verfahren zur ihrer herstellung und verwendung davon Ceased EP1061919A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04100891A EP1512683B1 (de) 1998-03-10 1999-03-09 Neue Opiate, Herstellungsverfahren und Verwendungen

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7740298P 1998-03-10 1998-03-10
US77402P 1998-03-10
US10790298P 1998-11-10 1998-11-10
US107902P 1998-11-10
PCT/US1999/005131 WO1999045925A1 (en) 1998-03-10 1999-03-09 Novel opiate compounds, methods of making and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04100891A Division EP1512683B1 (de) 1998-03-10 1999-03-09 Neue Opiate, Herstellungsverfahren und Verwendungen

Publications (2)

Publication Number Publication Date
EP1061919A1 EP1061919A1 (de) 2000-12-27
EP1061919A4 true EP1061919A4 (de) 2002-09-04

Family

ID=26759233

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04100891A Expired - Lifetime EP1512683B1 (de) 1998-03-10 1999-03-09 Neue Opiate, Herstellungsverfahren und Verwendungen
EP99912345A Ceased EP1061919A4 (de) 1998-03-10 1999-03-09 Neue opiate, verfahren zur ihrer herstellung und verwendung davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04100891A Expired - Lifetime EP1512683B1 (de) 1998-03-10 1999-03-09 Neue Opiate, Herstellungsverfahren und Verwendungen

Country Status (6)

Country Link
EP (2) EP1512683B1 (de)
JP (4) JP4498602B2 (de)
AT (1) ATE522503T1 (de)
AU (1) AU756983B2 (de)
CA (2) CA2683097A1 (de)
WO (1) WO1999045925A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
US6974825B1 (en) 1996-12-20 2005-12-13 Astrazeneca Canada Inc. Compounds with analgesic effect
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
US6110943A (en) * 1999-04-06 2000-08-29 American Home Products Corporation N-substituted (thiophen-2-yl)-piperidines and tetrahydropyridines as serotonergic agents
SE9904675D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
US6974824B2 (en) * 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
WO2002055495A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
WO2002055497A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
SE0101770D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101769D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101771D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101773D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
DK1735308T3 (da) * 2004-03-09 2009-01-19 Corcept Therapeutics Inc Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer
US7087749B2 (en) 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
WO2012094618A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
WO2013086496A2 (en) * 2011-12-09 2013-06-13 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3848027T3 (pl) 2013-11-25 2023-07-24 Corcept Therapeutics Incorporated Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego
EP4086249A3 (de) * 2015-09-02 2023-02-15 Trevena, Inc. 6-gliedrige heterozyklen mit delta-opioidrezeptor-modulierenden verbindungen, verfahren zur herstellung und verwendung davon
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132023A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
BR112021015129A2 (pt) 2019-02-22 2021-09-28 Corcept Therapeutics Incorporated Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma
EP4072556A4 (de) 2019-12-11 2024-01-03 Corcept Therapeutics Incorporated Verfahren zur behandlung von antipsychotikainduzierter gewichtszunahme mit miricorilant
CN112028878A (zh) * 2020-09-11 2020-12-04 江阴迈康升华医药科技有限公司 一种多氢异喹啉衍生物及其制备方法和医疗用途
WO2024026350A1 (en) * 2022-07-28 2024-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective opioid receptor agonists and antagonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018077A2 (de) * 1979-03-12 1980-10-29 Eli Lilly And Company Phenylmorphane, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
US5214148A (en) * 1990-12-18 1993-05-25 Glaxo Inc. Analgesic N-phenyl-N-(3-OR1 -3-ME-4-piperidinyl)amides
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
WO1999033806A1 (en) * 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
IT1307327B1 (it) * 1995-09-12 2001-10-30 Smithkline Beecham Spa Derivati idroisochinolinici sostituiti
SE9604786D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Inc New compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018077A2 (de) * 1979-03-12 1980-10-29 Eli Lilly And Company Phenylmorphane, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5214148A (en) * 1990-12-18 1993-05-25 Glaxo Inc. Analgesic N-phenyl-N-(3-OR1 -3-ME-4-piperidinyl)amides
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
WO1999033806A1 (en) * 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERTHA, C. M. ET AL.: "A Marked Change of Receptor Affinity of the 2-Methyl-5-(3-hydroxyphenyl)morphans upon Attachment of an (E)-8-Benzylidene Moiety: Synthesis and Evaluation of a New Class of .sigma. Receptor Ligands", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 19, 1994, pages 3163 - 3170, XP002203669 *
BERTHA, C. M. ET AL.: "Probes for arcotic Receptor-Mediated Phenomena. 20. Alteration of Opioid Receptor Subtype Selectivity of the 5-(3-Hydroxyphenyl)morphans by Application of the Message-Address Concept: Preparation of .delta.-Opioid Receptor Ligands", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 9, 1995, pages 1523 - 1537, XP002203668 *
CALDERON, S. N.: "Probes for Narcotic receptor Mediated Phenomena. 19. Synthesis of (1)-4-[(.alpha.R)-.alpha.((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide .delta. Opioid Receptor Agonist", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 14, 1994, pages 2125 - 2128, XP002203672 *
FROIMOWITZ M. ET AL.: "Phenylmorphans and Analogues: Opioid Receptor Subtype Selectivity and Effect of Conformation on Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 9, 1992, pages 1521 - 1525, XP002203667 *
ONG, H. H. ET AL.: "Phenylmorphan Agonists-Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 17, no. 1, 1974, pages 133 - 134, XP002203670 *
THOMAS J B ET AL: "A Stereoselective Synthetic Approach to N-Alkyl-4beta-methyl-5-phenyl morphans", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 40, no. 3, 15 January 1999 (1999-01-15), pages 403 - 406, XP004151342, ISSN: 0040-4039 *
THOMAS J B ET AL: "Optically Pure (-)-4-[(N-Allyl-3-Methyl-4-Piperidinyl)Phenylamino]-N, N-Diethylbenzamide Displays Selective Binding and Full Agonist Activity for the delta Opioid Receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 23, 6 December 1999 (1999-12-06), pages 3347 - 3350, XP004183736, ISSN: 0960-894X *
THOMAS, J. B. ET AL.: "N-substituted 9.beta.-Methyl-5-(3-hydroxyphenyl)morphans Are Opioid Receptor Pure Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 21, 1998, pages 4143 - 4149, XP002203671 *

Also Published As

Publication number Publication date
CA2324418A1 (en) 1999-09-16
AU3073899A (en) 1999-09-27
JP2010095542A (ja) 2010-04-30
EP1512683B1 (de) 2011-08-31
ATE522503T1 (de) 2011-09-15
JP2002506032A (ja) 2002-02-26
AU756983B2 (en) 2003-01-30
WO1999045925A1 (en) 1999-09-16
JP2010095543A (ja) 2010-04-30
JP4498602B2 (ja) 2010-07-07
JP2010143940A (ja) 2010-07-01
EP1512683A1 (de) 2005-03-09
EP1061919A1 (de) 2000-12-27
CA2683097A1 (en) 1999-09-16
CA2324418C (en) 2010-02-02

Similar Documents

Publication Publication Date Title
EP1061919A4 (de) Neue opiate, verfahren zur ihrer herstellung und verwendung davon
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
GR3029758T3 (en) N-acylated tricyclic azaheterorings useful as vasopressin antagonists.
UA81624C2 (ru) Тризамещённые гетероарилы и способ их получения и применение
IL172614A0 (en) Dual nk1/nk3 antagonists for treating schizophrenia
WO2002032874A3 (en) Substituted heterocyclic compounds for treating multidrug resistance
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
NO970162L (no) Substituerte pyrimidinforbindelser og anvendelse derav
HU0104085D0 (en) Method for the treatment of pulmonary hypertension
WO2002094767A3 (en) Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
WO2002037927A3 (en) Compounds and methods for promoting smoking cessation
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
MEP6708A (xx) Derivati n/tiayol/2/yl/benyamida
BG105710A (en) 5ht1 antagonists for antidepressant therapy
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.
ID27452A (id) Proses untuk membuat urea 1,3-tersubstitusi-4-oksosiklik
NO20030717D0 (no) Forbindelser for behandling av avhengighetsforstyrrelser
MX258626B (es) Proceso para la produccion de materiales de gasolina.
WO2002046157A3 (en) Methods for the stereoselective synthesis of substituted piperidines
ID27316A (id) Proses untuk membuat urea 1,3-terdisubstitusi-4-oksosiklik
DE69922918D1 (de) Neuropeptid Y Antagonisten
PT1315515E (pt) Utilização de eritropoietina, bem como dos seus derivados, para o tratamento de esquizofrenia e psicoses relacionadas

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RESEARCH TRIANGLE INSTITUTE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THOMAS, JAMES, B

Inventor name: MASCARELLA, S., WAYNE

Inventor name: CARROL; FRANK, IVY

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 211/22 A, 7A 61K 31/435 B, 7C 07D 221/22 B, 7C 07D 211/58 B, 7A 61K 31/445 B, 7C 07D 221/08 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020718

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040701